Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance of HIV Suppression with ddI/d4T/HU vs ddI/d4T/EFV vs PI Continuation
NCT00000939Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hydroxyurea, efavirenz, stavudine and didanosine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Plasma HIV RNA Level up to 3 years. Status: completed.
02
Drugs
hydroxyureaefavirenzstavudinedidanosine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000939.